Furthermore, with an innovative approach, a modified basket trial concept was applied to NAFLD preclinical models to discover a novel dipeptidyl peptidase-4 inhibitor-specific biomarker [217]. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.